Foghorn Therapeutics (FHTX) TD Cowen 46th Annual Health Care Conference summary

Strategic partnerships and pipeline overview

• Partnership with Eli Lilly includes a 50/50 collaboration on the SMARCA2 program, with additional targets under Lilly's rights and a significant oncology deal established in December 2021.

• Proprietary pipeline features selective CBP, EP300, and ARID1B degrader programs, with IND-enabling studies for CBP and EP300 expected later this year and in vivo proof of concept for ARID1B targeted for 2026.

• An I&I program with a novel target is projected for IND in 2027, pending continued validation.

• The company is advancing induced proximity approaches, with more developments anticipated over the next year.

• Recent $50 million direct offering extends financial runway by approximately two quarters at current burn rate.

Clinical progress and trial updates

• SMARCA2 program is in dose escalation, with no maximum tolerated dose reached; sites are open in the US, Japan, France, Germany, Spain, and South Korea.

• Backfilling of cohorts began in Q4, focusing on non-small cell lung cancer patients with strong loss-of-function SMARCA4 mutations.

• Decision on dose expansion is expected around mid-year, depending on ongoing phase 1 results.

• Enrollment has been efficient due to proactive site openings, facilitating seamless transition to expansion if warranted.

• Safety and tolerability have been favorable, with no dose-limiting toxicities reported to date.

Scientific and clinical rationale

• Chromatin regulatory system mutations are prevalent in oncology and other diseases, with selective drugging achieved after years of effort.

• SMARCA4-mutant non-small cell lung cancer patients have poor prognosis, especially when co-mutated with KRAS, highlighting high unmet need.

• Combination strategies with KRAS inhibitors are anticipated in future expansion phases.

• CBP and EP300 degraders show promising preclinical efficacy and improved safety profiles compared to dual bromodomain inhibitors.

• ARID1B degrader program is progressing, with selective degradation achieved and in vivo proof of concept targeted for 2026.